Insulin Dosing Articles & Analysis
2 articles found
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone. Such a fixed dose combination is already on the market under the brand name Xultophy, which is a ...
At Glooko, we believe being named a leader in CB Insights’ Diabetes Digital Therapeutics For Healthcare Payers — Execution & Market Strength Positioning (ESP) Vendor Matrix validates what our customers have been saying about our commitment to providing innovative digital health tools for chronic conditions like diabetes. Glooko was among the select companies that CB Insights ...